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ABSTRACT   
We recently developed a novel therapeutic particle, HerGa, for breast cancer treatment and detection. HerGa consists of 
a tumor-targeted cell penetration protein noncovalently assembled with a gallium-metallated corrole. The corrole is 
structurally   similar to porphyrin, emits intense fluorescence, and has proven highly effective for breast tumor treatment 
preclinically, without light exposure. Here, we tested HerGa as a photosensitizer for photodynamic therapy and 
investigated its mechanism of action using multimode optical imaging. Using confocal fluorescence imaging, we 
observed that HerGa disrupts the mitochondrial membrane potential in situ, and this disruption is substantially 
augmented by light exposure. In addition, spectral and fluorescence lifetime imaging were utilized to both validate the 
mitochondrial membrane potential disruption and investigate HerGa internalization, allowing us to optimize the timing 
for light dosimetry. We observed, using advanced multimode optical imaging, that light at a specific wavelength 
promotes HerGa cytotoxicity, which is likely to cause disruption of mitochondrial function. Thus, we can identify for the 
first time the capacity of HerGa as a photosensitizer for photodynamic therapy and reveal its mechanism of action, 
opening possibilities for therapeutic intervention in human breast cancer management. 
Keywords: Multimode optical imaging, targeted gallium corrole, photosensitizers, spectral imaging, fluorescence 
lifetime imaging.  
 
1. INTRODUCTION  
Porphyrin-like compounds have been widely used as photosensitizers in photodynamic therapy for various disease 
treatments (1, 2). In particular, several compounds, including Photofrin, Levulan, and Metvix, are already being used in 
the clinic for lung, esophageal, and bladder cancer treatment (3-5). However, corroles, which are macrocyclic 
compounds with a porphyrin-like structure, have not been thoroughly explored in biological systems until our own 
recent studies in vitro (6, 7) and in vivo (8). We have shown that the particle, HerGa, comprised of sulfonated gallium-
metallated corrole (S2Ga) complexed with the recombinant tumor-targeted cell penetrating protein, HerPBK10, is highly 
effective for tumor detection and treatment in an animal model of HER2+ breast cancer, which is a highly aggressive 
breast cancer that resists standard treatment. In addition, these studies revealed that HerPBK10 is non-immunogenic and 
facilitates the targeted systemic delivery of S2Ga to tumor cells in vivo through human epidermal growth factor receptor 
(HER) ligation, endocytosis, and endosomal penetration, enabling corrole-mediated cell killing (6). HerGa self-
assembles non-covalently while exhibiting high stability in serum. Unlike trastuzumab, HerPBK10 contains the receptor 
binding domain of heregulin, which has an enhanced affinity for tumors displaying elevated HER subunit 2 (HER2) but 
does not directly interact with HER2, thus avoiding tissue displaying normal HER2 levels (such as the heart), and hence 
indicating that HerGa may present an improved alternative strategy for HER2+ tumor killing compared to current 
targeted therapies (9-11).  
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Whereas HerGa is structurally similar to porphyrins (3-5), its photosensitizing potential has not been fully investigated, 
thus prompting an exploration of this possibility in the current study.  Here we used multimode optical imaging, 
including bright-field, fluorescence confocal, spectral, and lifetime imaging (6), to show that HerGa exhibits 
photosensitizer properties that augment its inherent cytotoxicity. This additional capability may enhance the potency and 
specificity of the drug for tumor treatment by combining with the inherent cytotoxicity of HerGa, thus further reducing 
drug dosage and consequently possible side-effects, as well as resulting in rapid translation into clinical use (1, 2).  
In this investigation, we apply multiple imaging techniques (including bright-field, fluorescence confocal, spectral, and 
lifetime imaging) that offer complementary and synergetic information in identifying the characteristics of molecules 
and their mechanism, resulting in eliminating potential blind spots, which can not ordinarily be detected using a single 
imaging mode (6).  These studies examine the effect of HerGa on mitochondrial membrane potential in MDA-MB-435 
cells -/+ light exposure by measuring the mitochondrial accumulation of a cationic fluorescent probe, tetramethyl 
rhodamine, methyl ester (TMRM) using confocal, bright-field, and spectral imaging. In addition, we examined HerGa 
uptake using fluorescence lifetime imaging in order to determine the optimal timing for light dosimetry on the cells.  
 
2. METHODS AND MATERIALS  
2.1 Materials 
MDA-MB-435 cells (National Cancer Institute) were cultured in Dulbecco’s modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum and penicillin/streptomycin at 37º C, 5% CO2. HerGa was produced through 
non-covalently binding of  HerPBK10 protein, which was expressed in Escherichia coli as a histidine-tagged fusion 
protein and purified by metal chelate affinity chromatography, to S2Ga at a molar ratio of 30:1 as previously described 
(7). TMRM was obtained from Invitrogen.  
 
2.2 Experimental setup for multimode optical imaging 
A Leica TCS SPE confocal and a Nikon TE 2000 microscope were used for multimode optical imaging. The Leica 
confocal imaging system was used for bright-field, confocal, and spectral imaging while the Nikon TE 2000 microscope, 
which is modified to connect multiple imaging devices (up to 4 devices) and deliver versatile laser lines, was utilized for 
fluorescence lifetime measurement. For live cell imaging, a delta T chamber was utilized in order to control temperature 
during image acquisition. A temperature-controlled stage integrated with the microscopes was used to control the 
temperature of samples. 
Mitochondrial damage by HerGa -/+ light was assessed by bright-field, confocal, and spectral imaging of the MDA-MB-
435 cells sequentially. 405nm and 535nm laser light were delivered to the samples through an objective (63x, NA: 1.3, 
Leica) for excitation of HerGa and TMRM respectively. The emitted light from the samples was filtered by a light 
wavelength selector, and then recorded in photomultiplier tubes (PMT). To discriminate between HerGa and TMRM 
fluorescence, thirteen images were acquired within the spectral range (530-650nm, with a step size, 10nm) for the 
spectral imaging and analysis, and then the images were analyzed using the spectral classification program we 
previously developed (12). Bright-field imaging, used to monitor morphological changes of the cells, was performed 
sequentially using the transmission mode of the Leica system [Fig. 1.(A)].  
For fluorescence lifetime imaging, femtosecond (fs) pulsed laser light (100fs) tuned to 424nm, at a repetition rate of 
80MHz, generated by the second harmonic of fs pulsed laser at 848nm in a Beta Barium Borate (BBO) crystal, was 
delivered to the Nikon Microscope through macro lenses, a band-pass filter (425±5nm), several mirrors, and a diffuser. 
The delivered light was reflected to the back focal plane of a 100x objective (Nikon 100x planfluor, NA: 1.3) for the 
excitation of HerGa. The fluorescence from HerGa was collected by the objective and recorded in the CCD connected 
with the time-gated intensifier (TGI) (Lavison) through an emission filter (620±60nm). The CCD and the time-gated 
intensifier were synchronized with pulsed light via a delay unit that connects with the external trigger [Figure 1.(B)].   
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Fig. 1. Experimental setup for multimode optical imaging: (A) confocal/bright-field/spectral imaging system 
(B) fluorescence lifetime imaging system. M: mirror, DM: dichroic mirror, AOTF: Acousto-optic tunable filters, 
L: tube lens, A: aperture, ES: light wavelength selector, PMT: photomultiplier tube, ΔT: delta T chamber, PL: 
polarizer, BS: beam sampler, PD: photodiode detector, FR: faraday rotator, L1, 2: doublet lens (focal lens: 15mm), 
BBO: beta barium borate crystal, F1: excitation filter (425±5nm), F2: emission filter (610nm±60nm), O: objective, 
TGI: time-gated intensifier, and CCD: charge-coupled detector. This figure was modified from the experimental 
setup reported previously [Jae Youn Hwang et al., submitted for publication].  
 
2.3 Mitochondrial membrane potential measurement 
TMRM is a cationic dye used to measure mitochondrial membrane potential in live cells. Its distribution across the 
mitochondrial membrane is governed primarily by the Nernst equation (13). To measure the mitochondrial membrane 
potential of HerGa treated cells -/+ light, 104 MDA-MB-435 cells were plated at four Delta T chambers and incubated 
for 36 hours, and then media was aspirated from each chamber and replaced with 1ml DMEM supplemented with 10% 
fetal bovine serum and penicillin/streptomycin containing either 1μM HerGa, 1μM S2Ga, HerPBK10 (at equivalent 
protein concentration as HerGa), or PBS at 37º C, 5% CO2. After the 24 hours, the media in the chambers was aspirated 
and replaced with 20nM TMRM diluted with HBSS, and then confocal TMRM fluorescence images were acquired -/+ 
light exposure (450nm-490nm, 17J/cm2) at different z-depths after the equilibrium of TMRM accumulation in the cells 
(~ 1 hour).  
3. RESULTS 
3.1 Confocal, bright-field and spectral imaging allow monitoring variations of mitochondrial membrane 
permeability by HerGa-mediated photosensitization, quantitatively  
To assess whether HerGa possesses photosensitizer activity, both mitochondrial membrane permeability and 
morphologic changes (indicating cellular health status) of MDA-MB-435 cells, confocal/bright-field/spectral imaging 
was performed after treatment with HerGa and other control molecules -/+ light exposure. Specifically, cells growing in 
delta T chambers were treated with 1μM HerGa, 1μM S2Ga, PBS, and HerPBK10 for 24 hours before addition of 
TMRM and TMRM fluorescence, bright-field, and spectral classified images were acquired sequentially [Fig. 2.] (14). 
In Figure 2.(A), without light exposure, there is still detectable TMRM accumulation in mitochondria and the cells 
exhibit similar morphology to that of healthy cells. However, after the light exposure, mitochondrial accumulation of 
TMRM is dramatically reduced while the cells exhibit a rounded, cytopathic morphology. Spectral imaging, which 
enables discrimination between HerGa and TMRM fluorescence signals quantitatively, was additionally performed -/+ 
light exposure. The spectral classification images, created by the spectral classification program we developed 
previously (12), show that after the light exposure, while HerGa (green pseudo-color) is indeed accumulated diffusely 
inside cells that have undergone mitochondrial disruption, TMRM (red pseudo-color) appears diffused away from 
mitochondria into the cytoplasm and outside cells. Figure 2.(B) shows the results for the control experiment.  Unlike 
Figure 2.(A), the mitochondrial membrane potential variations in control-treated cells -/+ light exposure were much less 
than in the HerGa-treated cells [Fig.2. (B)]. Taken together, these results show that the bright-field/confocal/spectral 
imaging allows us to monitor the mitochondrial membrane permeability and morphologic changes of the HerGa treated 
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cells -/+light quantitatively and specifically, thus revealing toxic properties of HerGa that are activated by 
photoexcitation.   
 
Fig. 2. Mitochondrial membrane potential variation of cells treated with HerGa, HerPBK10, S2GA, or PBS 
-/+ light exposure: (A) Confocal images of HerGa treated cell -/+ light (450nm-490nm, 17J/cm2). Left, TMRM 
fluorescence; Middle, spectral classified images. Red: TMRM. Green: HerGa.  Right, bright field images (B) 
confocal TMRM fluorescence images of S2Ga, HerPBK10, and PBS treated cells -/+ light (450nm-490nm, 
17J/cm2).  
3.2 Fluorescence lifetime changes of HerGa during internalization into MDA-MB-435 cells 
The results shown in Figure 2 indicate that light at specific wavelengths can promote mitochondrial damage in HerGa-
treated cells, but not significantly in S2Ga-treated cells, in which cellular uptake of S2Ga is much less than HerGa (8). 
The results suggest that cell entry is required for HerGa-mediated photosensitization, and indicate that light exposure 
should occur some time after the internalization of HerGa in order to induce its photosensitizing effect efficiently. Our 
previous studies show that HerPBK10-mediated delivery yields accumulation in endocytic vesicles by 15 min after 
uptake followed by sufficient cytosolic distribution of HerPBK10 by 45 min (8). Hence, we examined whether HerGa 
fluorescence lifetime could be used as a live-cell indicator to signal the optimal timing for light exposure within this 
established time window of uptake.  Figure 3 shows the fluorescence lifetime and intensity images of HerGa, which 
were obtained at the indicated time-points after the cells were exposed to 25 μM HerGa, during uptake. A higher than 
normal concentration of HerGa was used here to provide high signal to noise ratio for adequate fluorescence lifetime 
detection. In the Figure 3.(A), while the average fluorescence lifetime of HerGa on the cells is approximately 0.87ns 
(0.64~1.03ns) at 3 minutes, the average fluorescence lifetime of HerGa decreases to approximately 0.55ns at 30 minutes. 
Interestingly, the fluorescence lifetimes of HerGa (average: 0.58ns) at 60 minutes somewhat increases, but not 
significantly compared to at 30 minutes. This increase is likely to reflect the endosomal escape of HerGa, as cytosolic 
distribution takes place by 45 min after cell entry (8). The histograms [Fig. 3.(B)] detail the distribution of fluorescence 
lifetimes of HerGa. At 3 minutes, the histogram has peaks at 0.84ns and 0.94ns. The fluorescence lifetimes are of 
relatively low frequency below 0.8ns. On the other hand, the peaks at 30 and 60 minutes are shifted to around 0.48 ns 
Proc. of SPIE Vol. 7886  78860M-4
Downloaded From: http://proceedings.spiedigitallibrary.org/ on 10/28/2016 Terms of Use: http://spiedigitallibrary.org/ss/termsofuse.aspx
  
and 0.53ns respectively. Finally, the fluorescence intensity images show that while HerGa accumulates on cell 
membrane at 3 minutes, it is localized in the cytoplasm while remaining excluded from the nucleus after 30 minutes [Fig. 
3. (C)]. Altogether, these results show that initial HerGa uptake is realized within 30 minutes after the addition of HerGa 
onto the cells, thus allowing us to identify the optimal timing for inducing photoexcitation. Moreover, the fluorescence 
lifetime imaging enables us to monitor intracellular micro-environmental changes encountered during HerGa uptake, 
including those changes characterizing endosomal escape.   
. 
Fig. 3. Fluorescence lifetime changes of HerGa during the uptake: (A) fluorescence lifetime images of HerGa at the 
indicated time-points (B) histogram of fluorescence lifetime images (C) fluorescence intensity images. Scale bar: 5μm 
4. DISCUSSION AND CONCLUSIONS 
The mitochondrion is a common target for many photosensitizers (15, 16) and monitoring its membrane potential can be 
a powerful approach for identifying the toxic activity of various drugs (6, 17). Our present studies show that HerGa 
similarly causes mitochondrial membrane potential disruption through modulation by photoexcitation, and the 
multimode imaging used here allows us to characterize the events surrounding this activity intracellularly, in real-time, 
and in live cells.  Similar to other photosensitizers, HerGa requires membrane penetration to damage cells.  This is 
provided by the endosomolytic domain of HerPBK10, which is shown elsewhere to facilitate cytosolic delivery of 
corroles and nucleic acids (6-8).  In agreement, Figure 2 shows that corrole-mediated cell damage induced by 
photoexcitation occurs when S2Ga is delivered by HerPBK10 (in other words, by fully assembled HerGa), but not by 
HerPBK10 or S2Ga alone.  
Fluorescence lifetime imaging also enables us to characterize HerGa cell entry in real-time. Figure 3 shows that the 
fluorescence lifetimes of HerGa decrease as it is internalized into the cells. As our previous studies indicate that 
HerPBK10-mediated cell entry occurs by receptor-mediated endocytosis and endosomal escape (6, 7), the fluorescence 
lifetime changes of HerGa during uptake may reflect intracellular microenvironmental changes encountered during its 
transit. Particularly, the fluorescence lifetime increase of HerGa after 30 minutes may reflect the endosomal escape of 
HerGa.  As the microenviroment of the cytosol is less acidic than in endosomal vesicles, this could be indicative of pH 
changes, though this remains to be elucidated.  
In conclusion, these studies reveal that in addition to its reported inherent cytotoxicity (6, 7), HerGa also has 
photosensitizer activity that may augment its tumor-toxic potency. The multimode optical imaging used in the 
identification of the photosensitizer activity of HerGa and its mechanism of mitochondrial damage has also enabled real-
time characterization of the HerGa intracellular microenvironment during uptake. Thus, the multimode optical imaging 
has allowed the acquisition of complementary information that is not obtainable through single-mode imaging. 
Meanwhile, the combination of the inherent tumor-toxicity of HerGa and its newly discovered photo-reactivity may 
C
ount (n) 
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enable even greater potency and specificity for killing tumor cells, thus yielding a therapeutic with optimized efficacy 
and safety.  
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